Quoin Pharmaceuticals Ltd. (NASDAQ: QNRX) received FDA guidance during a Type C meeting that a single Phase 3 study could be sufficient to support U.S. marketing approval of its lead product QRX003 for Netherton Syndrome. The agency also expressed openness to alternative, innovative trial designs such as randomized withdrawal or delayed‑start studies, moving away from the traditional vehicle‑controlled design that the company had previously considered.
Prior to this meeting, Quoin had planned to conduct two Phase 3 studies to satisfy regulatory expectations. The FDA’s acknowledgment of a single pivotal study represents a significant shift that could reduce development time, lower costs, and accelerate patient access to the first FDA‑approved therapy for this orphan disease.
Quoin remains on track to initiate the pivotal Phase 3 program and to complete patient recruitment in 2026, with a potential NDA filing in 2027. The company will submit data from its ongoing Phase 2 and pediatric investigator studies before launching the Phase 3 program, ensuring alignment with FDA expectations. CEO Dr. Michael Myers said, “FDA acknowledged that a single Phase 3 study may be sufficient to support U.S. marketing approval of QRX003 for Netherton Syndrome,” adding, “With our established network of U.S. and EU clinical trial sites, we are confident that we will be in a position to initiate our pivotal Phase 3 program and fully complete recruitment this year.”
As a clinical‑stage company, Quoin reports no revenue and has approximately $5.4 million in cash, cash equivalents, and marketable securities as of September 30, 2025. With no debt and a strong interest coverage ratio, the company’s runway is expected to support operations through 2027, allowing it to fund the streamlined development path outlined by the FDA.
The announcement was positively received by investors, reflecting confidence in the streamlined development path and the potential to bring the first FDA‑approved treatment for Netherton Syndrome to market.
The content on EveryTicker is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.